Quantib, spin-off from Erasmus University Medical Center (Rotterdam - The Netherlands), and Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announce the signing of a distribution agreement for Myrian®. The new partners joined forces to accelerate Quantib’s product development, resulting in their CE cleared product Quantib® ND Plus, based on the Myrian® platform.
Quantib has been collaborating closely with Intrasense since 2016, developing this new medical imaging software dedicated to neurodegenerative diseases. Using Myrian® Studio, Quantib team accelerated the creation of the Quantib® ND Plus application. A distribution agreement is promoting Myrian® as platform of this innovative neuro application.
Quantib® ND Plus is a FDA cleared and CE marked imaging software solution, offering clinicians fast and accurate automated brain segmentation. Myrian® Studio perfectly matched R&D requirements, as a customizable industrial solution for development, enabling an optimal time-to-market.
Based on the Myrian® platform, Quantib® ND Plus provides a high-tech user-friendly general workstation including a variety of MRI brain scan analyses. It proposes a state of the art imaging solution for quantification, analysis and reporting in neurology.
Rudolf Scholte, CEO of Quantib, comments: «Collaborating with Intrasense provided us the opportunity to bring our brain segmentation solution to the market using a well-known and easy-to-use platform. The integration of Quantib® ND Plus with Myrian® Studio allows the user to deploy our advanced machine learning algorithms in a user-friendly environment.»
«This collaboration with Quantib is a very interesting partnership, supporting them in developing their technical solution and market offer for visualization technologies and medical imaging analysis. Myrian® Studio perfectly meets their needs, offering turn-key and optimized time-to-market solutions.» adds Nicolas Reymond, Director of Business Development & Operations at Intrasense.
Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled ‘innovative company’ by the BPI and invested more than 10 million euros in Research & Development since its creation.
For more information, please visit www.intrasense.fr.